Sagimet Biosciences, Inc. Class A (SGMT)
NASDAQ:SGMT
Want to see SGMT full AI Analyst Report?
Top Page
Sagimet Biosciences, Inc. Class A
(NASDAQ:SGMT)
Select Model
Select Model
Rating:56Neutral
Price Target:
$8.00
▲(23.65% Upside)
Action:ReiteratedDate:04/29/26
The score is held back primarily by weak financial performance (persistent losses and significant cash burn despite low leverage). Offsetting factors include strong technical momentum and positive pipeline/capital-raise corporate events that improve funding visibility and development progress, while valuation remains constrained by ongoing losses.
Positive Factors
Strengthened liquidity via equity offering
The underwritten public offering materially increases near-term funding and provides durable runway to execute planned development: it explicitly targets Phase 3 denifanstat in acne, TVB-3567 Phase 2 progress, IND-enabling work, and general corporate needs, reducing immediate refinancing pressure and enabling multi-period program advancement.
Negative Factors
High and rising cash burn
Sizable negative operating and free cash flow indicate the business cannot self-fund development and will continue to rely on external capital. Rising cash burn narrows optionality, forces prioritization across programs, and increases the likelihood of additional financings that can alter development timelines or strategic choices over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Strengthened liquidity via equity offering
The underwritten public offering materially increases near-term funding and provides durable runway to execute planned development: it explicitly targets Phase 3 denifanstat in acne, TVB-3567 Phase 2 progress, IND-enabling work, and general corporate needs, reducing immediate refinancing pressure and enabling multi-period program advancement.
Read all positive factors
Sagimet Biosciences, Inc. Class A (SGMT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$465.61M
Dividend YieldN/A
Average Volume (3M)365.43K
Price to Earnings (P/E)―
Beta (1Y)2.83
Revenue GrowthN/A
EPS Growth-9.59%
CountryUS
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.29
Shares Outstanding61,184,315
10 Day Avg. Volume392,336
30 Day Avg. Volume365,426
Financial Highlights & Ratios
PEG Ratio-0.42
Price to Book (P/B)1.72
Price to Sales (P/S)0.00
P/FCF Ratio-4.19
Enterprise Value/Market Cap0.45
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.67
Forecast
1Y Price Target
$25.11Price Target Upside288.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.44
Revenue Forecast (FY)$300.00K
Sagimet Biosciences, Inc. Class A Business Overview & Revenue Model
Company Description
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidat...
How the Company Makes Money
Sagimet Biosciences primarily makes money through the development and commercialization of its drug candidates. Revenue streams are potentially derived from partnerships, licensing agreements, and collaborations with larger pharmaceutical companie...
Sagimet Biosciences, Inc. Class A Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
68
Positive
Cash Flow
25
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 2.00M | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 2.00M | 0.00 | 0.00 |
| EBITDA | -56.89M | -45.57M | -30.74M | -31.05M | -23.72M |
| Net Income | -51.04M | -45.57M | -27.88M | -30.50M | -24.44M |
Balance Sheet | |||||
| Total Assets | 116.48M | 160.26M | 96.72M | 33.03M | 59.03M |
| Cash, Cash Equivalents and Short-Term Investments | 113.12M | 151.25M | 94.90M | 32.34M | 56.73M |
| Total Debt | 78.00K | 78.00K | 65.00K | 211.00K | 348.00K |
| Total Liabilities | 5.10M | 4.45M | 5.65M | 219.98M | 217.29M |
| Stockholders Equity | 111.38M | 155.81M | 91.06M | -186.95M | -158.26M |
Cash Flow | |||||
| Free Cash Flow | -45.65M | -42.44M | -23.77M | -24.49M | -21.71M |
| Operating Cash Flow | -45.65M | -42.44M | -23.77M | -24.49M | -21.71M |
| Investing Cash Flow | 4.56M | -61.68M | 12.58M | -32.01M | 0.00 |
| Financing Cash Flow | 275.00K | 104.82M | 86.17M | -73.00K | 9.74M |
Sagimet Biosciences, Inc. Class A Technical Analysis
Positive
6.47
Price Trends
5.37
Positive
5.78
Positive
6.89
Negative
Market Momentum
0.21
Negative
67.59
Neutral
95.69
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SGMT, the sentiment is Positive. The current price of 6.47 is above the 20-day moving average (MA) of 5.29, above the 50-day MA of 5.37, and below the 200-day MA of 6.89, indicating a neutral trend. The MACD of 0.21 indicates Negative momentum. The RSI at 67.59 is Neutral, neither overbought nor oversold. The STOCH value of 95.69 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SGMT.
Sagimet Biosciences, Inc. Class A Risk Analysis
Sagimet Biosciences, Inc. Class A disclosed 78 risk factors in its most recent earnings report. Sagimet Biosciences, Inc. Class A reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Sagimet Biosciences, Inc. Class A Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $148.95M | 6.18 | 17.46% | ― | ― | ― | |
57 Neutral | $444.57M | -1.84 | -46.34% | ― | ― | 2.37% | |
56 Neutral | $465.61M | -3.75 | -40.85% | ― | ― | -9.59% | |
55 Neutral | $562.90M | -2.96 | -39.83% | ― | -87.94% | -274.08% | |
53 Neutral | $327.29M | -1.34 | -121.73% | ― | ― | 1.79% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $242.62M | -3.23 | -90.51% | ― | 18.61% | 42.63% |
* Healthcare Sector Average
SGMT
Sagimet Biosciences, Inc. Class A
7.61
4.02
111.98%
CDXS
Codexis
2.67
0.16
6.37%
CABA
Cabaletta Bio
2.94
1.66
129.69%
BDTX
Black Diamond Therapeutics
2.60
0.93
55.69%
AVIR
Atea Pharmaceuticals
5.58
2.62
88.51%
TRDA
Entrada Therapeutics Inc
14.50
5.41
59.52%
Sagimet Biosciences, Inc. Class A Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Sagimet Biosciences Announces Major Equity Offering for Pipeline
Positive
Apr 28, 2026
On April 27, 2026, Sagimet Biosciences, Inc. entered into an underwriting agreement for an underwritten public offering of 29,166,700 shares of its Series A common stock at $6.00 per share, expected to generate net proceeds of about $164.5 million...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingProduct-Related Announcements
Sagimet Updates Investor Presentation After Key Clinical Milestones
Positive
Apr 27, 2026
Sagimet Biosciences Inc. is a biotechnology company developing novel fatty acid synthase (FASN) inhibitors targeting metabolic dysfunction and dermatologic diseases, with a particular focus on acne and metabolic dysfunction-associated steatohepati...
Business Operations and StrategyFinancial Disclosures
Sagimet Highlights Pipeline Progress and Strategic Corporate Developments
Positive
Apr 27, 2026
On April 27, 2026, Sagimet updated its investor slide presentation and issued a press release outlining strategic and corporate developments, including progress across its FASN‑inhibitor pipeline. The company highlighted that denifanstat ach...
Business Operations and StrategyExecutive/Board Changes
Sagimet Biosciences Appoints Andreas Grauer as Chief Medical Officer
Positive
Apr 21, 2026
On April 20, 2026, Sagimet Biosciences, Inc. Class A appointed Andreas Grauer, M.D., as its Chief Medical Officer, adding a seasoned drug development leader to its executive team. Grauer’s background spans senior medical roles at Omeros Corp...
Business Operations and StrategyFinancial Disclosures
Sagimet Biosciences Reports 2025 Results, Highlights Clinical Progress
Positive
Mar 11, 2026
Sagimet Biosciences reported its fourth-quarter and full-year 2025 results on March 11, 2026, highlighting clinical progress across its MASH and acne portfolios and solid liquidity of $113.1 million in cash, cash equivalents and marketable securit...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.